Global Injectable Drug Delivery Devices Market Overview

The Injectable Drug Delivery Devices Market is expected to grow at a significant growth rate, and the analysis period is 2022-2028, considering base year as 2021.

The technology utilized to deliver the drug to the target body site for drug release and absorption, or the subsequent transport of the active components across biological membranes to the site of action, is referred to as drug delivery. The method in which a drug is administered can have a substantial impact on its efficacy. The development of various drug delivery systems (DDSs) has enabled greater control of drug pharmacokinetics, pharmacodynamics, toxicity, immunogenicity, and efficacy. The best-suited delivery method for a specific drug molecule can optimize the performance of a specific drug inside the body. Injectable devices deliver drugs directly into the bloodstream. This is the best way to administer a drug quickly and precisely since the drug enters systemic circulation without the delay associated with absorption processes, exerting its therapeutic effect faster than any other route. Injectable drug administration is a traditional approach that is still widely used today. The rising number of people suffering from diabetes and chronic diseases has accelerated the growth of the injectable drug delivery device market.

Key Factors and Market Dynamics in Injectable Drug Delivery Devices:

Drivers

Next-Generation Drug Delivery Formulations - BeloGal Technology
New medication formulations that are not particularly water-soluble are becoming more common. It is estimated that 40% of medications with market approval and almost 90% of compounds in drug discovery pipelines are poorly soluble in aqueous solutions and/or have very low permeability to allow for sufficient and reproducible absorption from the gastrointestinal tract (GIT) following oral administration. BeloGal, a novel technology, offers a highly promising solution to nearly all formulation challenges of this type. It wraps the insoluble API in a biomimetic chemical polymer-based cover and directs the API to the liver or lung while avoiding other organs such as the heart. The majority of these medications are administered intravenously. Following the successful clinical development of the first BeloGal-based drug, the technology is expected to become the gold standard for intravenous drug delivery to the liver and lung, allowing for an entirely new level of innovation and clinical benefit for both drug delivery and organ-targeting, self-navigating drug formulations, thereby supporting the growth of the injectable drug delivery devices market throughout the forecast period.

Restraints

Contamination from previously used injectables and needlestick injuries can result in serious problems that require further remediation, and these complications frequently lead to additional challenges in disease management. In some circumstances, alternate medication delivery routes, such as oral administration, are favored over injections because they eliminate toxicity issues. Furthermore, strict regulations may restrict the usage of IDD forms. Several concerns have been raised in recent years about the sterility of injectables, which has resulted in a decrease in the number of approved production facilities that manufacture these products, and thus a shortage of these drugs in the market. Legal regulations by other countries on the usage of syringes for drug administration may hamper the growth of the injectable drug delivery devices market over the forecast period.

Opportunities

Microneedles-The Future of Drug Delivery
Microneedles, which are thinner than human hair, are frequently made from a hydrogel-forming polymer similar to that used to make soft contact lenses. Microneedles rapidly absorb fluid from the puncture site and swell, generating a jelly-like material while remaining rigid in a dry condition so that they can pierce the skin. Medicines can be administered into the body or biomarkers can be picked up for monitoring purposes via this relatively painless needle injection. Depending on their intended use, the needles can also be made as solid, coated, or hollow. After perforation, solid microneedles can carry pharmaceuticals into the skin, whereas coated microneedles have a film of medicine pasted over them that is then released into the body. Drugs can be injected directly into the skin through holes in the needles using hollow microneedles. This MedTech sector presents a lucrative opportunity for market participants, as demand for painless injectable devices is expected to rise throughout the forecasted timeframe.

Covid-19 Impact On Injectable Drug Delivery Devices Market

The COVID-19 pandemic has had devastating effects on several industry verticals globally. To constrain the number of cases and slow the coronavirus spread, various public health guidelines were implemented in different countries across the globe. COVID-19 protocols ranging from declaring national emergency states, enforcing stay-at-home orders, closing nonessential business operations and schools, banning public gatherings, imposing curfews, distributing digital passes, and allowing police to restrict citizen movements within a country, as well as closing international borders. The ability of Robo advisers to minimise irrational behaviour and bad & impulsive decision-making during a pandemic contributes significantly to the worldwide market's growth. With the growing vaccination rate, governments are uplifting the protocols to give a boost to the stagnant economy. Like other industries, Injectable Drug Delivery Devices Market have experienced slowdown the growth, however market is expected bounce back as restrictions are being lifted up by governments across the globe.

Market Segmentation

By type, the connected smart devices segment is anticipated to develop at the highest CAGR over the forecast period. Pharma 4.0 is accelerating the convergence of injection systems and information systems, including the development of a new generation of connected autoinjectors that combine personalized dosing with data capture and reporting capabilities. This delivery system not only simplifies dosing but also provides doctors and patients with a new level of digital visibility and insight into each course of therapy, helping the segment's growth. Due to the growing number of diabetic patients, the self-injectable category is expected to dominate the market. In recent years, the number of individuals that require injectable insulin has increased. Similarly, the number of patients suffering from spondylitis and cancer is also rising thus, strengthening the growth of the segment.

By parenteral route, the sub-cutaneous segment is expected to lead the growth of the injectable drug delivery devices market in the projected timeframe. A subcutaneous injection is given beneath the skin into the fat layer just below the dermis. Since the tissue areas have fewer blood arteries, absorption via the subcutaneous route is slow and sustained. It has a slower action than intravenous but a faster action than intradermal. Measles vaccine, insulin, goserelin, and morphine are some of the major drugs administered utilizing sub-cutaneous injections. The continuous rise in diabetic patients has stimulated the demand for sub-cutaneous injectable drug delivery devices. According to IDF, the total number of diabetic individuals was 537 million in 2021, which is expected to reach 643 million by 2030.

By end-users, the home care settings segment is anticipated to develop at the highest CAGR attributed to the rise in user-friendly injectable home medications. For instance, in May 2021, Eli Lilly and Company signed strategic international agreements with four companies: DexCom, Inc., Glooko Inc., myDiabby Healthcare, and Roche, to integrate data and technology to help streamline diabetes management. These firms provide distinct diabetes management solutions that will work with Lilly's Tempo Pen™ and Tempo Smart Button™. This will make the administration of insulin pens easier in homecare situations. Similar launches by other companies are expected to support the growth of the segment.

Players Covered in Injectable Drug Delivery Devices market are :

  • Becton
  • Dickinson and Company (U.S.)
  • Pfizer Inc. (U.S.)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Eli Lilly and Company (U.S.)
  • Baxter International Inc. (U.S.)
  • Schott AG (Germany)
  • Gerresheimer (Germany)
  • Ypsomed (Switzerland)
  • B. Braun Melsungen (Germany) and other major players.

Regional Analysis of Injectable Drug Delivery Devices Market:

The Asia-Pacific region is anticipated to lead the growth of the injectable drug delivery devices market during the projected timeframe attributed to the high density of the geriatric population. China and India are the most populated countries in the world. High population density and the prevalence of chronic disorders are the main factors that can upsurge the spread of viral infections. The COVID-19 pandemic that originated in China rapidly spread to the other parts of the Asian countries and the rest of the globe. As the number of patients were increasing, the demand for syringes also soared. Furthermore, the vaccination initiatives that were started utilized syringes for administration. Concomitantly, the number of patients having the chronic disorder, cancer, and other medical condition that requires injectable drugs is also rising thus, supporting the expansion of the market in this region.

The North American region is estimated to have the second highest share of the injectable drug delivery devices market owing to the growing diabetic population. According to IDF, in North America and the Caribbean, the number of diabetic individuals was 51 million in 2021, and it is projected to reach 63 million by 2045. The 24% rise in the diabetic population is estimated to boost the sales of injectable insulin. Moreover, the prevalence of seasonal influenza is further bolstering the growth of the market. According to CDC, for the 2020-2021 season, manufacturers have projected they will provide as many as 194 to 198 million doses of influenza vaccine for the U.S. market thus, stimulating the development of the injectable drug delivery devices market in this region.

The market in the European region is anticipated to grow at a significant growth rate attributed to the increasing prevalence of chronic diseases. More than half of European individuals suffer from neurological disorders. According to the European Academy of Neurology, approximately 308 million individuals had one or the other kind of neurological disorder in 2017. Furthermore, diabetes is also common in this region. According to IDF, 61 million population was estimated to be diabetic in 2021, projected to reach 69 million by 2045. Thus, the growing number of chronic disorders will strengthen the growth of the injectable drug delivery devices market.

Recent Industry Developments in Injectable Drug Delivery Devices Market:

  • In October 2021, in collaboration with Aptar Pharma, Becton, Dickinson, and Company (BD) developed the BD SCF PremiumCoat Plunger Stopperade to facilitate the injection of biologics into subcutaneous tissue using a -mL pre-filled syringe.
  • In October 2021, the world's first autoinjector for prefilled syringes with integrated connection was presented by Ypsomed. The YpsoMate autoinjector for prefilled syringes is a dependable and safe device for subcutaneous self-medication. These allow people with chronic conditions to treat themselves at home, reducing the strain on the medical system.

Global Injectable Drug Delivery Devices Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD XXX Bn.

Forecast Period 2022-28 CAGR:

XXX%

Market Size in 2028:

USD XXX Bn.

Segments Covered:

By Device Type

  • Conventional
  • Self-Injectable
  • Prefilled Syringes
  • Connected Smart Devices

By Parenteral Route

  • Intradermal
  • Subcutaneous
  • Intramuscular
  • Intravenous

By End Users

  • Hospitals
  • Homecare Settings
  • Clinics
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Next-Generation Drug Delivery Formulations - BeloGal Technology

Key Market Restraints:

  • Contamination from Previously Used Injectables and Needlestick Injuries

Key Opportunities:

  • Microneedles- The Future of Drug Delivery

Companies Covered in the report:

  • Becton Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), and Other major players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Device Type
 3.2 By Parenteral Route
 3.3 By End Users

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Injectable Drug Delivery Devices Market by Device Type
 5.1 Injectable Drug Delivery Devices Market Overview Snapshot and Growth Engine
 5.2 Injectable Drug Delivery Devices Market Overview
 5.3 Conventional
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Conventional: Grographic Segmentation
 5.4 Self-Injectable
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Self-Injectable: Grographic Segmentation
 5.5 Prefilled Syringes
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Prefilled Syringes: Grographic Segmentation
 5.6 Connected Smart Devices
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Connected Smart Devices: Grographic Segmentation

Chapter 6: Injectable Drug Delivery Devices Market by Parenteral Route
 6.1 Injectable Drug Delivery Devices Market Overview Snapshot and Growth Engine
 6.2 Injectable Drug Delivery Devices Market Overview
 6.3 Intradermal
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Intradermal: Grographic Segmentation
 6.4 Subcutaneous
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Subcutaneous: Grographic Segmentation
 6.5 Intramuscular
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Intramuscular: Grographic Segmentation
 6.6 Intravenous
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Intravenous: Grographic Segmentation

Chapter 7: Injectable Drug Delivery Devices Market by End Users
 7.1 Injectable Drug Delivery Devices Market Overview Snapshot and Growth Engine
 7.2 Injectable Drug Delivery Devices Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Grographic Segmentation
 7.4 Homecare Settings
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Homecare Settings: Grographic Segmentation
 7.5 Clinics
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Clinics: Grographic Segmentation
 7.6 Others
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size (2016-2028F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Others: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Injectable Drug Delivery Devices Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Injectable Drug Delivery Devices Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Injectable Drug Delivery Devices Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 BECTON
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 DICKINSON & COMPANY
 8.4 PFIZER INC.
 8.5 TEVA PHARMACEUTICALS INDUSTRIES LTD.
 8.6 ELI LILLY & COMPANY
 8.7 BAXTER INTERNATIONAL INC.
 8.8 SCHOTT AG
 8.9 GERRESHEIMER
 8.10 YPSOMED
 8.11 B. BRAUN MELSUNGEN
 8.12 OTHER MAJOR PLAYERS

Chapter 9: Global Injectable Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Device Type
  9.2.1 Conventional
  9.2.2 Self-Injectable
  9.2.3 Prefilled Syringes
  9.2.4 Connected Smart Devices
 9.3 Historic and Forecasted Market Size By Parenteral Route
  9.3.1 Intradermal
  9.3.2 Subcutaneous
  9.3.3 Intramuscular
  9.3.4 Intravenous
 9.4 Historic and Forecasted Market Size By End Users
  9.4.1 Hospitals
  9.4.2 Homecare Settings
  9.4.3 Clinics
  9.4.4 Others

Chapter 10: North America Injectable Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Device Type
  10.4.1 Conventional
  10.4.2 Self-Injectable
  10.4.3 Prefilled Syringes
  10.4.4 Connected Smart Devices
 10.5 Historic and Forecasted Market Size By Parenteral Route
  10.5.1 Intradermal
  10.5.2 Subcutaneous
  10.5.3 Intramuscular
  10.5.4 Intravenous
 10.6 Historic and Forecasted Market Size By End Users
  10.6.1 Hospitals
  10.6.2 Homecare Settings
  10.6.3 Clinics
  10.6.4 Others
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Injectable Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Device Type
  11.4.1 Conventional
  11.4.2 Self-Injectable
  11.4.3 Prefilled Syringes
  11.4.4 Connected Smart Devices
 11.5 Historic and Forecasted Market Size By Parenteral Route
  11.5.1 Intradermal
  11.5.2 Subcutaneous
  11.5.3 Intramuscular
  11.5.4 Intravenous
 11.6 Historic and Forecasted Market Size By End Users
  11.6.1 Hospitals
  11.6.2 Homecare Settings
  11.6.3 Clinics
  11.6.4 Others
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Injectable Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Device Type
  12.4.1 Conventional
  12.4.2 Self-Injectable
  12.4.3 Prefilled Syringes
  12.4.4 Connected Smart Devices
 12.5 Historic and Forecasted Market Size By Parenteral Route
  12.5.1 Intradermal
  12.5.2 Subcutaneous
  12.5.3 Intramuscular
  12.5.4 Intravenous
 12.6 Historic and Forecasted Market Size By End Users
  12.6.1 Hospitals
  12.6.2 Homecare Settings
  12.6.3 Clinics
  12.6.4 Others
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Injectable Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Device Type
  13.4.1 Conventional
  13.4.2 Self-Injectable
  13.4.3 Prefilled Syringes
  13.4.4 Connected Smart Devices
 13.5 Historic and Forecasted Market Size By Parenteral Route
  13.5.1 Intradermal
  13.5.2 Subcutaneous
  13.5.3 Intramuscular
  13.5.4 Intravenous
 13.6 Historic and Forecasted Market Size By End Users
  13.6.1 Hospitals
  13.6.2 Homecare Settings
  13.6.3 Clinics
  13.6.4 Others
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Injectable Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Device Type
  14.4.1 Conventional
  14.4.2 Self-Injectable
  14.4.3 Prefilled Syringes
  14.4.4 Connected Smart Devices
 14.5 Historic and Forecasted Market Size By Parenteral Route
  14.5.1 Intradermal
  14.5.2 Subcutaneous
  14.5.3 Intramuscular
  14.5.4 Intravenous
 14.6 Historic and Forecasted Market Size By End Users
  14.6.1 Hospitals
  14.6.2 Homecare Settings
  14.6.3 Clinics
  14.6.4 Others
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

Global Injectable Drug Delivery Devices Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD XXX Bn.

Forecast Period 2022-28 CAGR:

XXX%

Market Size in 2028:

USD XXX Bn.

Segments Covered:

By Device Type

  • Conventional
  • Self-Injectable
  • Prefilled Syringes
  • Connected Smart Devices

By Parenteral Route

  • Intradermal
  • Subcutaneous
  • Intramuscular
  • Intravenous

By End Users

  • Hospitals
  • Homecare Settings
  • Clinics
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Next-Generation Drug Delivery Formulations - BeloGal Technology

Key Market Restraints:

  • Contamination from Previously Used Injectables and Needlestick Injuries

Key Opportunities:

  • Microneedles- The Future of Drug Delivery

Companies Covered in the report:

  • Becton Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), and Other major players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. INJECTABLE DRUG DELIVERY DEVICES MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. INJECTABLE DRUG DELIVERY DEVICES MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. INJECTABLE DRUG DELIVERY DEVICES MARKET COMPETITIVE RIVALRY
TABLE 005. INJECTABLE DRUG DELIVERY DEVICES MARKET THREAT OF NEW ENTRANTS
TABLE 006. INJECTABLE DRUG DELIVERY DEVICES MARKET THREAT OF SUBSTITUTES
TABLE 007. INJECTABLE DRUG DELIVERY DEVICES MARKET BY DEVICE TYPE
TABLE 008. CONVENTIONAL MARKET OVERVIEW (2016-2028)
TABLE 009. SELF-INJECTABLE MARKET OVERVIEW (2016-2028)
TABLE 010. PREFILLED SYRINGES MARKET OVERVIEW (2016-2028)
TABLE 011. CONNECTED SMART DEVICES MARKET OVERVIEW (2016-2028)
TABLE 012. INJECTABLE DRUG DELIVERY DEVICES MARKET BY PARENTERAL ROUTE
TABLE 013. INTRADERMAL MARKET OVERVIEW (2016-2028)
TABLE 014. SUBCUTANEOUS MARKET OVERVIEW (2016-2028)
TABLE 015. INTRAMUSCULAR MARKET OVERVIEW (2016-2028)
TABLE 016. INTRAVENOUS MARKET OVERVIEW (2016-2028)
TABLE 017. INJECTABLE DRUG DELIVERY DEVICES MARKET BY END USERS
TABLE 018. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 019. HOMECARE SETTINGS MARKET OVERVIEW (2016-2028)
TABLE 020. CLINICS MARKET OVERVIEW (2016-2028)
TABLE 021. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 022. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DEVICE TYPE (2016-2028)
TABLE 023. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PARENTERAL ROUTE (2016-2028)
TABLE 024. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USERS (2016-2028)
TABLE 025. N INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2028)
TABLE 026. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DEVICE TYPE (2016-2028)
TABLE 027. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PARENTERAL ROUTE (2016-2028)
TABLE 028. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USERS (2016-2028)
TABLE 029. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2028)
TABLE 030. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DEVICE TYPE (2016-2028)
TABLE 031. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PARENTERAL ROUTE (2016-2028)
TABLE 032. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USERS (2016-2028)
TABLE 033. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DEVICE TYPE (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PARENTERAL ROUTE (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USERS (2016-2028)
TABLE 037. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2028)
TABLE 038. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DEVICE TYPE (2016-2028)
TABLE 039. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PARENTERAL ROUTE (2016-2028)
TABLE 040. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USERS (2016-2028)
TABLE 041. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2028)
TABLE 042. BECTON: SNAPSHOT
TABLE 043. BECTON: BUSINESS PERFORMANCE
TABLE 044. BECTON: PRODUCT PORTFOLIO
TABLE 045. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. DICKINSON & COMPANY: SNAPSHOT
TABLE 046. DICKINSON & COMPANY: BUSINESS PERFORMANCE
TABLE 047. DICKINSON & COMPANY: PRODUCT PORTFOLIO
TABLE 048. DICKINSON & COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. PFIZER INC.: SNAPSHOT
TABLE 049. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 050. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 051. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. TEVA PHARMACEUTICALS INDUSTRIES LTD.: SNAPSHOT
TABLE 052. TEVA PHARMACEUTICALS INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 053. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 054. TEVA PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. ELI LILLY & COMPANY: SNAPSHOT
TABLE 055. ELI LILLY & COMPANY: BUSINESS PERFORMANCE
TABLE 056. ELI LILLY & COMPANY: PRODUCT PORTFOLIO
TABLE 057. ELI LILLY & COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. BAXTER INTERNATIONAL INC.: SNAPSHOT
TABLE 058. BAXTER INTERNATIONAL INC.: BUSINESS PERFORMANCE
TABLE 059. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 060. BAXTER INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. SCHOTT AG: SNAPSHOT
TABLE 061. SCHOTT AG: BUSINESS PERFORMANCE
TABLE 062. SCHOTT AG: PRODUCT PORTFOLIO
TABLE 063. SCHOTT AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. GERRESHEIMER: SNAPSHOT
TABLE 064. GERRESHEIMER: BUSINESS PERFORMANCE
TABLE 065. GERRESHEIMER: PRODUCT PORTFOLIO
TABLE 066. GERRESHEIMER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. YPSOMED: SNAPSHOT
TABLE 067. YPSOMED: BUSINESS PERFORMANCE
TABLE 068. YPSOMED: PRODUCT PORTFOLIO
TABLE 069. YPSOMED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. B. BRAUN MELSUNGEN: SNAPSHOT
TABLE 070. B. BRAUN MELSUNGEN: BUSINESS PERFORMANCE
TABLE 071. B. BRAUN MELSUNGEN: PRODUCT PORTFOLIO
TABLE 072. B. BRAUN MELSUNGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 073. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 074. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 075. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY DEVICE TYPE
FIGURE 012. CONVENTIONAL MARKET OVERVIEW (2016-2028)
FIGURE 013. SELF-INJECTABLE MARKET OVERVIEW (2016-2028)
FIGURE 014. PREFILLED SYRINGES MARKET OVERVIEW (2016-2028)
FIGURE 015. CONNECTED SMART DEVICES MARKET OVERVIEW (2016-2028)
FIGURE 016. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY PARENTERAL ROUTE
FIGURE 017. INTRADERMAL MARKET OVERVIEW (2016-2028)
FIGURE 018. SUBCUTANEOUS MARKET OVERVIEW (2016-2028)
FIGURE 019. INTRAMUSCULAR MARKET OVERVIEW (2016-2028)
FIGURE 020. INTRAVENOUS MARKET OVERVIEW (2016-2028)
FIGURE 021. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY END USERS
FIGURE 022. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 023. HOMECARE SETTINGS MARKET OVERVIEW (2016-2028)
FIGURE 024. CLINICS MARKET OVERVIEW (2016-2028)
FIGURE 025. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 026. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Injectable Drug Delivery Devices Market research report?

The forecast period in the Injectable Drug Delivery Devices Market research report is 2022-2028.

Who are the key players in Injectable Drug Delivery Devices Market?

Becton Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Baxter International Inc. (U.S.), Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), B. Braun Melsungen (Germany), and other major players.

What are the segments of the Injectable Drug Delivery Devices Market?

The Injectable Drug Delivery Devices Market is segmented into Device Type, Parenteral Route, End Users, and region. By Device Type, the market is categorized into Conventional, Self-Injectable, Prefilled Syringes, Connected Smart Devices. By Parenteral Route, the market is categorized into Intradermal, Subcutaneous, Intramuscular, Intravenous. By End Users, the market is categorized into Hospitals, Homecare Settings, Clinics, Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Injectable Drug Delivery Devices Market?

The technology utilized to deliver the drug to the target body site for drug release and absorption, or the subsequent transport of the active components across biological membranes to the site of action, is referred to as drug delivery.

How big is the Injectable Drug Delivery Devices Market?

The Injectable Drug Delivery Devices Market is expected to grow at a significant growth rate, and the analysis period is 2022-2028, considering base year as 2021.